Ind-Swift Laboratories Ltd. (INDSWFTLA) Share Price Within 2% of 52-Week High
- August 17, 2026
- Posted by: Harsh Piplani
- Category: News
Ind-Swift Laboratories Ltd. Share Price is Rs 314.9, with the stock trading within 2% of its 52-week high. Market capitalisation stands at Rs 2,645.37 crore.
Ind-Swift Laboratories Ltd. Share Price is Rs 314.9 as of 17 August 2026 at 9:30 AM IST, and the stock is trading within 2% of its 52-week high, according to the Univest screener. With a market capitalisation of Rs 2,645.37 crore, the move is notable because it places the pharmaceutical stock close to its one-year peak while valuation and profitability metrics present a more mixed picture.
The event-time last traded price identified by Univest was also Rs 314.9 at 9:30:41 AM IST. The supplied data confirms the proximity to the yearly high, but it does not establish a company-specific catalyst behind the move. Even so, stocks approaching their 52-week high often draw attention because investors use that zone to judge momentum, relative strength and whether the broader market is assigning a higher multiple to the business.
For readers tracking Ind-Swift Laboratories Ltd. Share Price Today, the immediate story is not just the headline price level. It is the combination of a near-peak trading position, a P/E ratio of 46.15, a P/B ratio of 1.77, ROE of -0.78 and ROCE of 8.31 within the Healthcare sector. That is why Ind-Swift Laboratories Ltd. Stock News is likely to remain on investor watchlists, especially on Univest, where price context, sector benchmarks and peer comparisons can be viewed together.
Ind-Swift Laboratories Ltd. Share Price Today: Within 2% of 52-Week High
| Metric | Value |
|---|---|
| LTP at 2% Qualification | Rs 314.9 |
| Market Capitalisation | Rs 2,645.37 crore |
| 52-Week High Position | Trading within 2% of its 52-week high |
Ind-Swift Laboratories Ltd. (INDSWFTLA) traded at Rs 314.9. Reported volume was 52,492.
Ind-Swift Laboratories Ltd. Share Price Today is Rs 314.9, and the Univest screener has identified the stock as trading within 2% of its 52-week high. The qualification price captured for the event was Rs 314.9, which means the stock was already in that closely watched upper range when the screen was triggered at 9:30:41 AM IST on 17 August 2026.
That matters because the 52-week high zone is often used by market participants as a reference point for strength. A stock trading near its one-year peak can indicate sustained buying interest over time, even when the supplied dataset does not by itself explain the underlying trigger. In practical terms, the market is still valuing Ind-Swift Laboratories Ltd. Share Price close to the top end of its 12-month range, and that alone can keep the counter in focus through the trading session.
For Ind-Swift Laboratories Ltd. Share Price, this event also stands out because the company’s market capitalisation of Rs 2,645.37 crore places it among the larger names in its same-industry benchmark set. When a stock of that size approaches its yearly high, investors often shift attention from price alone to whether the move is supported by earnings power, balance-sheet quality and sector-relative valuation.
In short, the price action shows a stock holding a strong zone on the chart. The next step is to examine whether the underlying fundamentals and industry comparisons justify the premium attention now surrounding Ind-Swift Laboratories Ltd. Share Price.
Ind-Swift Laboratories Ltd. (INDSWFTLA) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 2,645.37 crore |
| P/E Ratio | 46.15x |
| P/B Ratio | 1.77x |
| ROE | -0.78% |
| ROCE | 8.31% |
| EPS | Rs 6.59 |
| Book Value Per Share | Rs 171.98 |
| Dividend Yield | 0% |
Ind-Swift Laboratories Ltd. was valued at a P/E ratio of 46.15x, a P/B ratio of 1.77x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of -0.78% and ROCE of 8.31%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Per-share and shareholder-return metrics included EPS of Rs 6.59, book value per share of Rs 171.98, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 46.15x |
| Benchmark Median P/E | 19.11x |
| Benchmark Average P/E | 30.32x |
| Benchmark P/E Range | 0x to 361.02x |
| Company P/B Ratio | 1.77x |
| Benchmark Median P/B | 1.76x |
| Company ROE | -0.78% |
| Benchmark Median ROE | 9.91% |
| Company ROCE | 8.31% |
| Benchmark Median ROCE | 12.79% |
| Company Market Capitalisation | Rs 2,645.37 crore |
| Benchmark Median Market Cap | Rs 137.36 crore |
Ind-Swift Laboratories Ltd. (INDSWFTLA) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Ind-Swift Laboratories Ltd. (INDSWFTLA) has a P/E ratio of 46.15x, which is above the benchmark median of 19.11x, a difference of +141.5%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Ind-Swift Laboratories Ltd. (INDSWFTLA) has a ROE of -0.78%, which is below the benchmark median of 9.91%, a difference of -107.87%. Ind-Swift Laboratories Ltd. (INDSWFTLA) has a ROCE of 8.31%, which is below the benchmark median of 12.79%, a difference of -35.03%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Fredun Pharmaceuticals Ltd. | FREDUN | 2,559.68 | 58.41 | 8.73 | 11.42 | 13.15 |
| Beta Drugs Ltd. | BETA | 2,827.67 | 68.16 | 6.74 | 18.65 | 22.17 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,438.25 | 171 | 3.13 | 13.9 | 12.97 |
| Venus Remedies Ltd. | VENUSREM-BE | 2,388.41 | 20.56 | 3.48 | 9.85 | 7.89 |
| Dishman Carbogen Amcis Ltd. | DCAL | 2,985.15 | 184.72 | 0.45 | -2.89 | -0.26 |
Ind-Swift Laboratories Ltd. (INDSWFTLA) has a P/E ratio of 46.15x compared with the displayed peer median of 68.16x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -0.78% compares with a peer median of 11.42% across the companies shown in the table. ROCE stood at 8.31% versus the displayed peer median of 12.97%, providing a capital-efficiency comparison. Ind-Swift Laboratories Ltd. (INDSWFTLA) has a market capitalisation of Rs 2,645.37 crore. Among the 5 peers shown, 2 have a larger market capitalisation.
Why Investors Are Watching Ind-Swift Laboratories Ltd.
- Ind-Swift Laboratories Ltd. Share Price is Rs 314.9 and the stock is trading within 2% of its 52-week high, a level many investors track for relative strength.
- The company’s market capitalisation of Rs 2,645.37 crore makes it a sizable name within the Pharmaceuticals & Drugs benchmark universe.
- Valuation is notable, with P/E at 46.15 versus the same-industry median of 19.11 and average of 30.32.
- P/B at 1.77 is close to the industry median of 1.76, suggesting a different picture on balance-sheet valuation than on earnings valuation.
- Profitability remains mixed, with ROE at -0.78 and ROCE at 8.31, both below same-industry medians.
- Peer comparisons show Ind-Swift Laboratories Ltd. Share Price sits among similarly sized healthcare names with widely varying valuation and return profiles.
About Ind-Swift Laboratories Ltd.
Ind-Swift Laboratories Ltd. is classified in the Healthcare sector and the Pharmaceuticals & Drugs industry. Based on the supplied company context, the stock sits within a closely tracked segment of the Indian market where investors regularly compare valuation multiples, profitability ratios and market capitalisation against listed pharma peers.
For readers following Ind-Swift Laboratories Ltd. Share Price, that industry classification matters because pharmaceuticals stocks are often judged not only on price movement but also on how efficiently they convert capital into returns. In this case, the company is being compared with a 138-company same-industry benchmark and with listed peers such as Fredun Pharmaceuticals, Beta Drugs, Sai Parenteral’s, Venus Remedies and Dishman Carbogen Amcis.
That positioning gives Ind-Swift Laboratories Ltd. visibility within a broad listed healthcare universe. It also means that any move toward a yearly high is quickly assessed against sector valuation norms, peer return ratios and company size. On Univest, this combination of price proximity, sector classification and peer context is exactly what makes Ind-Swift Laboratories Ltd. Stock News relevant for active market trackers.
Track Ind-Swift Laboratories Ltd. Share Price on Univest
Use Ind-Swift Laboratories Ltd. (INDSWFTLA) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Investors tracking Ind-Swift Laboratories Ltd. Share Price can use Univest to follow live price movement, 52-week levels, valuation ratios, profitability metrics, sector comparisons and peer benchmarks in one place. For a stock trading close to its yearly high, that consolidated view helps separate headline momentum from deeper financial context.
Univest also allows users to monitor how Ind-Swift Laboratories Ltd. Share Price compares with the Healthcare sector and the Pharmaceuticals & Drugs industry on metrics such as P/E, P/B, ROE, ROCE and market capitalisation. When a stock is within 2% of its 52-week high, keeping those ratios alongside peer data can be more useful than watching price alone.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is Ind-Swift Laboratories Ltd. Share Price today?
Ans. Ind-Swift Laboratories Ltd. Share Price was Rs 314.9 at the time of qualification on 17 August 2026 at 9:30:41 AM IST. The stock was also identified by the Univest screener as trading within 2% of its 52-week high.
Why is Ind-Swift Laboratories Ltd. Share Price in focus today?
Ans. Ind-Swift Laboratories Ltd. Share Price is in focus because the stock is trading within 2% of its 52-week high. With a market capitalisation of Rs 2,645.37 crore, that proximity puts valuation and sector comparisons under closer watch.
What does the current valuation say about Ind-Swift Laboratories Ltd. Share Price?
Ans. Ind-Swift Laboratories Ltd. Share Price trades at a P/E of 46.15 and a P/B of 1.77. The P/E is above the same-industry median of 19.11, while the P/B is almost in line with the median of 1.76.
How profitable is Ind-Swift Laboratories Ltd. based on the supplied ratios?
Ans. The supplied profitability ratios are mixed. ROE stands at -0.78, which is below the same-industry median of 9.91, while ROCE is 8.31 versus the industry median of 12.79, showing weaker return efficiency than the benchmark.
What are the key per-share fundamentals for Ind-Swift Laboratories Ltd.?
Ans. EPS is Rs 6.59, book value per share is Rs 171.98 and dividend yield is 0. These figures show the earnings base, accounting net worth and payout profile currently associated with Ind-Swift Laboratories Ltd. Share Price.
How large is Ind-Swift Laboratories Ltd. within its industry?
Ans. With a market capitalisation of Rs 2,645.37 crore, Ind-Swift Laboratories Ltd. is much larger than the same-industry median of Rs 137.36 crore and the average of Rs 465.84 crore across the 138-company benchmark universe.
How does Ind-Swift Laboratories Ltd. compare with selected pharma peers?
Ans. Ind-Swift Laboratories Ltd. sits near peers such as Fredun, Beta Drugs, Sai Parenteral's, Venus Remedies and Dishman Carbogen Amcis on market value, but its ROE of -0.78 and ROCE of 8.31 are mixed against several competitors.
Where can investors track Ind-Swift Laboratories Ltd. Share Price regularly?
Ans. Investors can track Ind-Swift Laboratories Ltd. Share Price on Univest for live price updates, 52-week levels, valuation ratios, sector comparison and peer data. That helps place near-high price action in a broader analytical framework.
